Cyclin-Dependent Kinase Inhibitor Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis, TYK Medicine, BioTheryX, Concarlo Therapeutics,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cyclin-Dependent Kinase Inhibitor pipeline constitutes 45+ key companies continuously working towards developing 52+ Cyclin-Dependent Kinase Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cyclin-Dependent Kinase Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Cyclin-Dependent Kinase Inhibitor Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cyclin-Dependent Kinase Inhibitor Market.

Some of the key takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report: https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cyclin-Dependent Kinase Inhibitor treatment therapies with a considerable amount of success over the years.
• Cyclin-Dependent Kinase Inhibitor companies working in the treatment market are Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others, are developing therapies for the Cyclin-Dependent Kinase Inhibitor treatment
• Emerging Cyclin-Dependent Kinase Inhibitor therapies in the different phases of clinical trials are- SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others are expected to have a significant impact on the Cyclin-Dependent Kinase Inhibitor market in the coming years.
• In July 2025, In the PALMARES-2 trial (NCT06805812), a multicenter study published in Annals of Oncology, the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)-abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali)-showed differing real-world progression-free survival (rwPFS) outcomes in patients with endocrine-sensitive, HR-positive/HER2-negative advanced breast cancer.
• In September 2024, Carrick Therapeutics Inc., a biopharmaceutical company focused on oncology and the development of innovative therapies, has announced that the first patient has been dosed in a Phase 1 clinical trial of CT7439. This novel agent functions as a CDK12/13 inhibitor and Cyclin-K glue-degrader. CDK12/13 plays a key role in various cancers by regulating transcription elongation, RNA splicing, and mRNA processing. Inhibition of CDK12/13 particularly suppresses DNA damage response genes. The trial is currently enrolling patients with advanced solid tumors, including ovarian, breast cancer, and Ewing's sarcoma.

Cyclin-Dependent Kinase Inhibitor Overview
Cyclin-Dependent Kinase Inhibitors (CDKIs) are a class of molecules that regulate the activity of cyclin-dependent kinases (CDKs), which are critical enzymes involved in the regulation of the cell cycle. CDKs control the progression of cells through the cell cycle by phosphorylating specific target proteins. The activity of CDKs is tightly regulated by the binding of cyclins, their regulatory subunits, and CDKIs.

Get a Free Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cyclin-Dependent Kinase Inhibitor Drugs Under Different Phases of Clinical Development Include:
• SY-5609: Syros Pharmaceutical
• XL 102: Exelixis
• PRT3645: Prelude Therapeutics
• BLU 222: Blueprint Medicines
• Enitociclib: Vincerx Pharma
• SHR-6390: Jiangsu Hengrui Medicine Co.
• Milciclib: Tiziana Life Sciences
• XZP 3287: Xuanzhu Biopharmaceutical
• Abemaciclib: Eli Lilly and Company
• GB491 (lerociclib): Genor Pharma
• Auceliciclib: Aucentra Therapeutics/University of South Australia
• AU2-94: Aucentra Therapeutics

Cyclin-Dependent Kinase Inhibitor Route of Administration
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Cyclin-Dependent Kinase Inhibitor Molecule Type
Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics Assessment
• Cyclin-Dependent Kinase Inhibitor Assessment by Product Type
• Cyclin-Dependent Kinase Inhibitor By Stage and Product Type
• Cyclin-Dependent Kinase Inhibitor Assessment by Route of Administration
• Cyclin-Dependent Kinase Inhibitor By Stage and Route of Administration
• Cyclin-Dependent Kinase Inhibitor Assessment by Molecule Type
• Cyclin-Dependent Kinase Inhibitor by Stage and Molecule Type

DelveInsight's Cyclin-Dependent Kinase Inhibitor Report covers around 52+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cyclin-Dependent Kinase Inhibitor product details are provided in the report. Download the Cyclin-Dependent Kinase Inhibitor pipeline report to learn more about the emerging Cyclin-Dependent Kinase Inhibitor therapies
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Cyclin-Dependent Kinase Inhibitor Therapeutics Market include:
Key companies developing therapies for Cyclin-Dependent Kinase Inhibitor are - MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, Exelixis, -Qurient Co. Ltd., OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others.

Cyclin-Dependent Kinase Inhibitor Pipeline Analysis:
The Cyclin-Dependent Kinase Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
• Cyclin-Dependent Kinase Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor drugs and therapies
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cyclin-Dependent Kinase Inhibitor Pipeline Market Drivers
• Rising prevalence of Cancer, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Cyclin-Dependent Kinase Inhibitor Market.

Cyclin-Dependent Kinase Inhibitor Pipeline Market Barriers
• However, high cost associated with the treatment, side-effects associated with the Cyclin-Dependent Kinase Inhibitor immunotherapy and other factors are creating obstacles in the Cyclin-Dependent Kinase Inhibitor Market growth.

Scope of Cyclin-Dependent Kinase Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others
• Key Cyclin-Dependent Kinase Inhibitor Therapies: SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others
• Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment: Cyclin-Dependent Kinase Inhibitor current marketed and Cyclin-Dependent Kinase Inhibitor emerging therapies
• Cyclin-Dependent Kinase Inhibitor Market Dynamics: Cyclin-Dependent Kinase Inhibitor market drivers and Cyclin-Dependent Kinase Inhibitor market barriers

Request for Sample PDF Report for Cyclin-Dependent Kinase Inhibitor Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Cyclin-Dependent Kinase Inhibitor Report Introduction
2. Cyclin-Dependent Kinase Inhibitor Executive Summary
3. Cyclin-Dependent Kinase Inhibitor Overview
4. Cyclin-Dependent Kinase Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics
6. Cyclin-Dependent Kinase Inhibitor Late Stage Products (Phase II/III)
7. Cyclin-Dependent Kinase Inhibitor Mid Stage Products (Phase II)
8. Cyclin-Dependent Kinase Inhibitor Early Stage Products (Phase I)
9. Cyclin-Dependent Kinase Inhibitor Preclinical Stage Products
10. Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment
11. Cyclin-Dependent Kinase Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cyclin-Dependent Kinase Inhibitor Key Companies
14. Cyclin-Dependent Kinase Inhibitor Key Products
15. Cyclin-Dependent Kinase Inhibitor Unmet Needs
16 . Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers
17. Cyclin-Dependent Kinase Inhibitor Future Perspectives and Conclusion
18. Cyclin-Dependent Kinase Inhibitor Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.